Cabenuva: A Novel Long-Acting Injectable HIV Treatment

Cabenuva is the first FDA-approved long-acting (LA) injectable regimen for patients with HIV infection.¹ Cabenuva (ViiV Healthcare) consists of cabotegravir (CAB), an integrase strand transfer inhibitor (INSTI), and rilpivirine (RPV), a non-nucleoside reverse transcriptase inhibitor (NNRTI) approved to replace antiretroviral therapy (ART) in patients with HIV-RNA less than 50 copies/mL who